Palonosetron

Yang, Lily; Scott, Lesley J.

doi:10.2165/11200980-000000000-00000

Cited by 63 publications

(32 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, pain of pelvic or visceral origin has been suggested as a significant cause of PONV 28. Although palonosetron and ramosetron are both 5-HT3 receptor antagonists, palonosetron is structurally distinct from first-generation drugs and exhibits allosteric binding and positive cooperativity 29. However, whether palonosetron has greater efficacy after abdominal or pelvic surgery is not known and cannot be judged from the present analysis.…”

Section: Discussionmentioning

confidence: 89%

Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials

et al. 2017

View full text Add to dashboard Cite

PurposeThis study was designed as a meta-analysis of randomized controlled trials (RCTs) that included the comparison of palonosetron and ramosetron for postoperative nausea and vomiting (PONV) prophylaxis.Materials and MethodsA systematic search was conducted for the PubMed, EMBASE, Web of Science, CENTRAL, KoreaMed, and Google Scholar databases (PROSPERO protocol number CRD42015026009). Primary outcomes were the incidences of postoperative nausea (PON) and postoperative vomiting (POV) during the first 48 hrs after surgery. The total 48-hr period was further analyzed in time epochs of 0–6 hrs (early), 6–24 hrs (late), and 24–48 hrs (delayed). Subgroup analyses according to number of risk factors, sex, and type of surgery were also performed.ResultsEleven studies including 1373 patients were analyzed. There was no difference in PON or POV between the two drugs for the total 48-hr period after surgery. However, palonosetron was more effective in preventing POV during the delayed period overall [relative risk (RR), 0.59; 95% confidence interval (CI), 0.39 to 0.89; p=0.013], as well as after subgroup analyses for females and laparoscopies (RR, 0.56; 95% CI, 0.36 to 0.86; p=0.009 and RR, 0.46; 95% CI, 0.23 to 0.94; p=0.033). Subgroup analysis for spine surgery showed that ramosetron was more effective in reducing POV during the total 48-hr (RR, 3.34; 95% CI, 1.46 to 7.63; p=0.004) and early periods (RR, 8.47; 95% CI, 1.57 to 45.72; p=0.013).ConclusionThis meta-analysis discovered no definite difference in PONV prevention between the two drugs. The significant findings that were seen in different time epochs and subgroup analyses should be confirmed in future RCTs.

show abstract

Section: Discussionmentioning

confidence: 89%

Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The 5-HT 3 receptor antagonist palonosetron has a greater binding affinity and longer half-life than other 5-HT 3 receptor antagonist [19]. The unique pharmacokinetics of palonosetron have been associated with clinical outcomes including better prevention of chemotherapy-induced nausea and vomiting compared with other 5-HT 3 drugs [20].…”

Section: Discussionmentioning

confidence: 99%

Effects of pretreatment with intravenous palonosetron for propofol-remifentanil-based anesthesia in breast and thyroid cancer surgery: a double-blind, randomized, controlled study

Lee¹,

Rim²,

Lee³

et al. 2014

Korean J Anesthesiol

View full text Add to dashboard Cite

BackgroundWe postulated that palonosetron, a novel antiemetic agent, might have the effect of alleviating injection pain from propofol and rocuronium. A double-blind, controlled study was undertaken to evaluate the effect of palonosetron on injection pain during total intravenous anesthesia and postoperative nausea and vomiting (PONV) using propofol-remifentanil in breast and thyroid cancer surgery.MethodsSixty patients were randomly allocated to one of two groups. Before injection of propofol and rocuronium, patients in group S (n = 30) received 4 ml of saline and patients in group P (n = 30) received 75 µg (1.5 ml) of palonosetron mixed with 2.5 ml of saline (n = 30). Patients were evaluated by a blinded anesthesiologist with regard to the scoring of injection pain of propofol, withdrawal response by rocuronium, PONV, shivering, postoperative pain, recall of pain, and overall satisfaction.ResultsThe differences between groups in the incidence of injection pain due to propofol and rocuronium were insignificant. However, in group P, the severity of propofol-induced injection pain (3% vs. 33%, P = 0.003) and postoperative pain (P = 0.038) was significantly lower during the first 12 h after surgery. No differences were observed between the groups with respect to PONV, shivering, recall of pain, and overall satisfaction.ConclusionsWe concluded that pretreatment of palonosetron was effective to reduce the severity of propofol-induced injection pain and early postoperative pain, although it did not reduce the incidence of injection pain from propofol and rocuronium.

show abstract

“…In the US, FDA has already approved for oral formulation of palonosetron for CINV. [20] An effective dose of palonosetron 0.50 mg oral has been favored for the prevention of CINV in patients receiving moderately emetogenic chemotherapy without a side effect disadvantage. Probably, this single dose in high risk patient before anesthesia may prevent PONV.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic

et al. 2014

View full text Add to dashboard Cite

Many anti-emetics are used in clinical practice. Palonosetron hydrochloride is one of them. It is a novel, centrally acting antiemetic, and anti-nausea agent. This drug is an antagonist of serotonin receptor subtype 3 (5-HT3). This drug has longer duration of action which makes it useful in the prevention and treatment of acute and delayed onset of nausea and vomiting. This drug was initially used for chemotherapy induced nausea and vomiting. Federal drug agency (FDA) has approved it for prevention and treatment of post-operative nausea and vomiting. The literature search for this article was done using Google scholar and Pubmed using the terms “Palonosetron,” “longer duration of action,” “nausea,” “vomiting,” and “postoperative”.

show abstract

Palonosetron

Cited by 63 publications

References 57 publications

Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials

Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials

Effects of pretreatment with intravenous palonosetron for propofol-remifentanil-based anesthesia in breast and thyroid cancer surgery: a double-blind, randomized, controlled study

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic

Contact Info

Product

Resources

About